Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

FLAVIVACCINE Development and characterization of a pan-flavivirus vaccine candidate

Coordinator
Institut De Recherche Pour Le Developpement, France
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€8.3m
Total cost
€8.3m
Partners
12 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101137006

What the project is doing

In the project's own words, from its summary on CORDIS.

Dengue, yellow fever, Zika, and West Nile viruses are mosquito-borne flaviviruses and global public health burdens that infect half a billion people annually, causing 250,000 deaths, and threaten nearly the entire human population. In a context of human-driven global changes, these threats will intensify with larger and more frequent epidemics, potentially leading to pandemics, will expand with geographic spreading of the mosquito vectors, and will multiply with the likely emergence of yet-unknown flaviviruses.

Improving pandemic preparedness and response to these emerging and re-emerging diseases is a top priority both for the EU and WHO. However, there are no effective interventions against all flaviviruses and current vaccines targeting flaviviral proteins have severe safety issues. FLAVIVACCINE’s high-impact/low-risk/disruptive ambition is to develop a novel, broad-spectrum, mosquito saliva-targeted vaccine candidate that protects against multiple different flaviviruses and is ready for clinical evaluation by building upon an experimentally-validated proof-of-concept.

FLAVIVACCINE will define the immunogenicity of the pan-flavivirus target, develop and characterize a vaccine candidate against multiple flaviviruses, and prepare it for clinical evaluation. To reach these goals, FLAVIVACCINE creates a unique interdisciplinary environment of ten public and private institutions, including Universities, Research Institutions and a Vaccine Developer, from seven countries to cover all the required scientific expertise and knowledge in cell biology, virology, immunology and vaccinology.

The pan-flavivirus vaccine candidate that will be validated against dengue, yellow fever, Zika and West Nile diseases in several preclinical models, together with the knowledge and networks resulting from FLAVIVACCINE, will have short- and long-term impact on the EU ability to combat epidemic and pandemic viral threats, and protect communities and citizens in the EU and around the world.

Who is involved

OrganisationCityCountryRole
Institut De Recherche Pour Le DeveloppementMarseilleFranceCoordinator
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Commissariat a L Energie Atomique Et Aux Energies AlternativesParisFranceParticipant
Institut PasteurParisFranceParticipant
Fondazione IconsLodiItalyParticipant
Universiteit UtrechtUtrechtNetherlandsParticipant
Norce Research ASBergenNorwayParticipant
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalParticipant
Conserv Bioscience LimitedLondonUnited KingdomAssociatedpartner
Pleguezuelos OlgaBicesterUnited KingdomAssociatedpartner
The Geneva FoundationTacomaUnited StatesParticipant
The Regents of the University of CaliforniaOaklandUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI